文章：

belantamab mafodotin 治疗复发性多发性骨髓瘤的“真实世界”疗效与安全性数据——来自梅奥诊所的经验

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

原文发布日期：2021-12-07

DOI: 10.1038/s41408-021-00592-3

类型: Article

开放获取: 是

英文摘要：

Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report the outcomes of 36 patients treated at Mayo Clinic. Our cohort received a median of eight prior lines of therapy. Six patients received belantamab in combination with other medications (pomalidomide, cyclophosphamide, thalidomide), 13 patients (36%) were 70 years or older, two patients had a creatinine of >2.5 mg/dL, and one patient was on dialysis. All three patients with renal failure received full dose belantamab. Chimeric antigen receptor (CAR-T) therapy was used prior to belantamab in seven patients and none of them responded to belantamab therapy. The overall response rate (ORR) was 33% (CR 6%, VGPR 8%, PR 19%), like the ORR reported in the DREAMM-2 trial. Keratopathy developed in 16 patients (43%), grade 1 in six patients, grade 2 in seven patients, and grade 3 in three patients. Eight percent discontinued therapy due to keratopathy. The median PFS and OS was 2 months and 6.5 months, respectively.
 

摘要翻译： 

Belantamab mafodotin是一种针对多发性骨髓瘤的高选择性靶向疗法。它靶向浆细胞上的B细胞成熟抗原（BCMA），并在多项随机临床试验中显示出良好疗效。本文报告了梅奥诊所收治的36例患者的治疗结果。该队列患者先前接受过中位八线治疗。其中6例患者接受belantamab联合其他药物（泊马度胺、环磷酰胺、沙利度胺）治疗，13例患者（36%）年龄在70岁及以上，2例患者肌酐水平＞2.5mg/dL，1例患者接受透析治疗。所有三例肾功能衰竭患者均接受了全剂量belantamab治疗。7例患者在belantamab治疗前接受过嵌合抗原受体T细胞（CAR-T）疗法，且均未对belantamab治疗产生应答。总缓解率（ORR）为33%（完全缓解6%、非常好的部分缓解8%、部分缓解19%），与DREAMM-2试验报告的ORR相似。16例患者（43%）出现角膜病变，其中1级6例、2级7例、3级3例。8%的患者因角膜病变中止治疗。中位无进展生存期（PFS）和总生存期（OS）分别为2个月和6.5个月。

原文链接：

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience